CodeMap® 
150 North Wacker Drive
Suite 2360
Chicago, IL 60606
847-381-5465 Phone
847-381-4606 Fax
customerservice@codemap.com
      


User Information

Create New Account

Lost Password

Username:
Password:


Quick Links

LCDs and LCAs
by Contractor

PLA Codes

Laboratory Fee Schedule

2024
2023

Physician Fee Schedule

2024
2023

OPPS Fee Schedule

2024-April
2024-January

ASC Fee Schedule

2024-April
2024-January

APC Codes

2024-April
2024-January

DRG Codes

2024
2023

ASP Drug Pricing Files

April 2024
January 2024


CMS Transmittals




National Coverage Determination
Procedure Code: 8XXXX
Prothrombin Time (PT)
CMS Policy Number: 190.17
Back to NCD List

Description: Basic plasma coagulation function is readily assessed with a few simple laboratory tests: the Partial Thromboplastin Time (PTT), Prothrombin Time (PT), Thrombin Time (TT), or a quantitative fibrinogen determination. The PT test is one in-vitro laboratory test used to assess coagulation. While the PTT assesses the intrinsic limb of the coagulation system, the PT assesses the extrinsic or tissue factor dependent pathway. Both tests also evaluate the common coagulation pathway involving all the reactions that occur after the activation of factor X. Extrinsic pathway factors are produced in the liver and their production is dependent on adequate vitamin K activity. Deficiencies of factors may be related to decreased production or increased consumption of coagulation factors. The PT/INR is most commonly used to measure the effect of warfarin and regulate its dosing. Warfarin blocks the effect of vitamin K on hepatic production of extrinsic pathway factors.

A PT is expressed in seconds and/or as an international normalized ratio (INR). The INR is the PT ratio that would result if the WHO reference thromboplastin was used in performing the test.

Current medical information does not clarify the role of laboratory PT testing in patients who are self monitoring. Therefore, the indications for testing apply regardless of whether or not the patient is also PT self-testing.

Indications:
1. A PT may be used to assess patients taking warfarin. The PT is generally not useful in monitoring patients receiving heparin who are not taking warfarin.

2. A PT may be used to assess patients with signs or symptoms of abnormal bleeding or thrombosis. For example:

  • Swollen extremity with or without prior trauma
  • Unexplained bruising
  • Abnormal bleeding, hemorrhage or hematoma
  • Petechiae or other signs of thrombocytopenia that could be due to Disseminated Intravascular Coagulation

    3. A PT may be useful in evaluating patients who have a history of a condition known to be associated with the risk of bleeding or thrombosis that is related to the extrinsic coagulation pathway. Such abnormalities may be genetic or acquired. For example:

  • Dysfibrinogenemia
  • Afibrinogenemia (complete)
  • Acute or chronic liver dysfunction or failure, including Wilson’s disease and Hemochromatosis
  • Disseminated intravascular coagulation (DIC)
  • Congenital and acquired deficiencies of factors II, V, VII, X
  • Vitamin K deficiency
  • Lupus erythematosus
  • Hypercoagulable state
  • Paraproteinemia
  • Lymphoma
  • Amyloidosis
  • Acute and chronic leukemias
  • Plasma cell dyscrasia
  • HIV infection
  • Malignant neoplasms
  • Hemorrhagic fever
  • Salicylate poisoning
  • Obstructive jaundice
  • Intestinal fistula
  • Malabsorption syndrome
  • Colitis
  • Chronic diarrhea
  • Presence of peripheral venous or arterial thrombosis or pulmonary emboli or myocardial infarction
  • Patients with bleeding or clotting tendencies
  • Organ transplantation
  • Presence of circulating coagulation inhibitors

    4. A PT may be used to assess the risk of hemorrhage or thrombosis in patients who are going to have a medical intervention known to be associated with increased risk of bleeding or thrombosis. For example:

  • Evaluation prior to invasive procedures or operations of patients with personal history of bleeding or a condition associated with coagulopathy.
  • Prior to the use of thrombolytic medication

    Limitations:
    1. When an ESRD patient is tested for PT, testing more frequently than weekly requires documentation of medical necessity, e.g., other than chronic renal failure or renal failure unspecified.

    2. The need to repeat this test is determined by changes in the underlying medical condition and/or the dosing of warfarin. In a patient on stable warfarin therapy, it is ordinarily not necessary to repeat testing more than every two to three weeks. When testing is performed to evaluate a patient with signs or symptoms of abnormal bleeding or thrombosis and the initial test result is normal, it is ordinarily not necessary to repeat testing unless there is a change in the patient’s medical status.

    3. Since the INR is a calculation, it will not be paid in addition to the PT when expressed in seconds, and is considered part of the conventional PT test.

    4. Testing prior to any medical intervention associated with a risk of bleeding and thrombosis (other than thrombolytic therapy) will generally be considered medically necessary only where there are signs or symptoms of a bleeding or thrombotic abnormality or a personal history of bleeding, thrombosis or a condition associated with a coagulopathy. Hospital/clinic-specific policies, protocols, etc., in and of themselves, cannot alone justify coverage.

    Frequency Limitations: When an ESRD patient is tested for PT, testing more frequently than weekly requires documentation of medical necessity [e.g. other than Chronic Renal Failure (ICD-9-CM 585) or Renal Failure, Unspecified (ICD-9-CM 586)].

    The need to repeat this test is determined by changes in the underlying medical condition and/or the dosing of warfarin. In a patient on stable warfarin therapy, it is ordinarily not necessary to repeat testing more than every two to three weeks.



    To review all requirements of this policy, please see: CMS NCD listing by Chapter

    Covered ICD-10 Codes.

    A01.00Typhoid fever, unspecified
    A01.01Typhoid meningitis
    A01.02Typhoid fever with heart involvement
    A01.03Typhoid pneumonia
    A01.04Typhoid arthritis
    A01.05Typhoid osteomyelitis
    A01.09Typhoid fever with other complications
    A01.1Paratyphoid fever A
    A01.2Paratyphoid fever B
    A01.3Paratyphoid fever C
    .... and many more.


    Sorry, you need to login or register to view additional sections of this Medicare policy.

    Click here for publications catalog.
    --

    The content and format of the following files and/or webpages are copywritten and the property of Wheaton Partners, LLC - dba CodeMap®. All recipients of these files agree not to distribute, reproduce and/or use the information contained within, in any manner not expressly agreed upon by the user and Wheaton Partners, LLC - dba CodeMap®.

    All code-pairs and Medicare coverage information are compiled directly from Center for Medicare and Medicaid Services (CMS) and Medicare Contractor coverage policies. CodeMap® has made every reasonable effort to ensure the accuracy of the information contained. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. Both CMS and Medicare contractor coverage policy information may change at any time. CodeMap® makes no representation, warranty, or guarantee that this compilation of coverage policy information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.


  • CodeMap® is a Registered Trademark of Wheaton Partners, LLC.